Abstract
The current focus of Crohn’s disease therapy has been long sclerosed. Biologics produce temporary remissions in 40% of cases. They have yet to induce permanent remissions. FDA’s reliance on clinical validation through comparative, placebo controlled, double-blinded studies has created an impediment to acceptance of divergent alternated therapies as being within the standard of care. In so doing, FDA has basically has surrendered the therapeutic dialogue of Crohn’s disease to those who can pay from such studies.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
